Company
Headquarters: Paiania, Greece
Employees: 251
€132.3 Million
EUR as of Jan. 1, 2024
US$146.1 Million
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AbbVie | $285.06 B |
Roche | $240.44 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; over the counter (OTC) drugs, such as antiseptics, and analgesics; gynecological products; and anti-lice treatment drugs. It also provides transdermal drug delivery systems (TDDS) related to pain management, hypertension, angina pectoris, Parkinson disease, asthma, female or male hormone replacement therapy, contraception, nausea, incontinence, etc. In addition, the company's product pipeline includes nicotine TDDS for smoking cessation; TDDS for hypertension; range of OTC products for common cold, oral hygiene, excessive excretion of shawl; food supplements; and anti-ageing products. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Lavipharm SA has the following listings and related stock indices.
Stock: ASE: LAVI wb_incandescent